Biomy Partners with 10x Genomics to Advance AI-Driven Virtual Cell foundation models Using Xenium

Collaboration will support development of foundation models to predict therapeutic response and enable biomarker discovery from spatial data

TOKYO, JAPAN – June, 4, 2026 – Biomy, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Teppei Konishi; hereinafter “Biomy”), a technology company focused on advancing personalized medicine through AI, today announced a partnership with 10x Genomics (NASDAQ: TXG), a leader in single cell and spatial biology, to develop AI-driven Virtual Cell foundation models powered by data generated using 10x’s Xenium platform.

Through the collaboration, Biomy plans to leverage 10x’s Xenium in situ platform to generate high-resolution spatial transcriptomics datasets for training foundation models designed to predict therapeutic response, support target discovery and enable biomarker identification. By combining spatial biology with advanced machine learning, the partnership aims to help researchers better understand tissue biology and accelerate the development of more precise therapeutic strategies.

Biomy will lead development of AI models and analytical workflows, while 10x will provide technical and scientific support to enable the effective use of its spatial technologies.[K1] 

“Xenium provides the high-quality, spatially resolved data needed to train the next generation of AI models in biology,” said Teppei Konishi, CEO of Biomy, Inc. “By integrating Xenium data into our AI platform, we are working to build Virtual Cell foundation models that can help predict how patients may respond to therapies and uncover novel biomarkers and targets.”

“Xenium enables researchers to generate highly multiplexed, in situ gene expression data at subcellular resolution, which is well-suited for training advanced models,” said Di Mo, Vice President, Sales, Asia-Pacific at 10x Genomics. “We’re excited to support Biomy as they apply these capabilities to develop Virtual Cell approaches for therapeutic response prediction and biomarker discovery.”

About Biomy, Inc.

Biomy, Inc. is a technology company focused on advancing personalized medicine through artificial intelligence. The company develops computational platforms for analyzing complex biological data, including spatial and imaging datasets, with the goal of enabling deeper insights into disease biology and supporting therapeutic development. For more information, visit: https://www.biomy-tech.com/

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.